ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes

The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline.

Analyst Commentary

Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary. The range of views gives you a clearer picture of how execution on Nuplazid, Daybue, and the broader pipeline is feeding into valuation assumptions.

Bullish Takeaways

Bullish analysts point to updated models after the Q4 report, with some price targets set in the low to mid US$30s. This reflects confidence that current commercial products and the pipeline can support higher long term revenue assumptions.
Several firms highlight 2026 guidance of US$1.2b to US$1.3b in total sales as a key input for their targets. They view current execution on Daybue and Nuplazid as supportive of their growth frameworks.
Positive views on remlifanserin in Alzheimer's disease psychosis are a key upside angle. Some analysts argue that this asset is underappreciated and could become an important driver for the equity story if trial results are supportive.
Initiations and upgrades to more positive ratings indicate that some on the Street view the current share price as reflecting the value of Nuplazid and Daybue alone. In their view, optionality from pipeline assets is not fully reflected.

Bearish Takeaways

Bearish analysts, or those more cautious, have trimmed price targets into the mid US$20s. They emphasize that while guidance and current sales are supportive, execution risk and pipeline uncertainty still matter for valuation.
Some target cuts into the low US$30s show that even positive ratings can come with more conservative assumptions. Analysts are adjusting models for factors such as product mix, timelines, or expense expectations.
Neutral stances paired with mid US$20s targets suggest that for some, the current valuation already reflects near term expectations for Nuplazid and Daybue. In this view, there is limited room for upside without clearer evidence from late stage pipeline assets.
A reduction in at least one target to US$29 while keeping a Neutral view shows that not all on the Street see the risk or reward as skewed positively, especially where guidance, regional approvals, or model changes introduce uncertainty.

What's in the News

DAYBUE STIX, a dye and preservative free powder formulation of trofinetide for oral solution, is now broadly available in the United States for adults and pediatric patients 2 years and older with Rett syndrome. It offers an alternative to the original oral solution with different dose volume and taste options (Key Developments).
The U.S. FDA approved DAYBUE STIX in December 2025 as a bioequivalent formulation to the original DAYBUE oral solution, based on a bioequivalence study and the pivotal Phase 3 LAVENDER trial. Both formulations remain available for patients (Key Developments).
A steering group of experts at IRSF designated centers of excellence published recommendations that recognize trofinetide oral solution as part of the standard of care for individuals with Rett syndrome. The recommendations emphasize early initiation, sustained use, and individualized treatment decisions (Key Developments).
The CHMP of the EMA issued a negative opinion on Acadia's Marketing Authorization Application for trofinetide in Rett syndrome, citing concerns about the magnitude of treatment effect, symptom coverage, and long term outcomes. Acadia plans to request a re examination of this opinion (Key Developments).
Acadia issued full year 2026 guidance for total revenues of US$1.22b to US$1.28b, including expected NUPLAZID net sales of US$760 million to US$790 million and DAYBUE net sales of US$460 million to US$490 million (Key Developments).

Valuation Changes

Fair Value: The updated estimate has risen slightly from $31.21 to $31.80 per share.
Discount Rate: The assumption has edged up from 7.09% to 7.10%, indicating a modest change in required return.
Revenue Growth: The long term revenue growth assumption has moved higher from 11.22% to 13.61%.
Net Profit Margin: The projected net profit margin has eased from 18.71% to 18.26%.
Future P/E: The expected future P/E multiple has shifted slightly lower from 25.02x to 24.51x.

23 views

Key Takeaways

Expanding product demand, strong pipeline progress, and strategic outreach are broadening the patient base and diversifying revenue streams, reducing reliance on single products.
Favorable regulatory trends and industry consolidation are enabling faster market access and unlocking new partnership and growth opportunities.
High reliance on a single drug, rising costs, regulatory risks, and intensifying competition pose significant threats to future growth and profitability.

Catalysts

About ACADIA Pharmaceuticals

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.What are the underlying business or industry changes driving this perspective?

Sustained demand for DAYBUE and NUPLAZID, driven by aging populations and increasing prevalence of CNS disorders worldwide, is expanding the company's total addressable market and supporting ongoing double-digit revenue growth.
Investment in direct-to-consumer campaigns and community physician outreach for both DAYBUE and NUPLAZID is leading to increased brand awareness and penetration outside of traditional academic centers, supporting higher patient persistency rates and broadening the patient base, which bolsters future revenue and stabilizes margins.
ACADIA's pipeline momentum-with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027-positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.
Positive regulatory and reimbursement trends for rare and neurological diseases, including the use of named patient supply channels globally and favorable FDA review paths, are enabling faster and broader market access for new therapies, likely accelerating revenue growth and international market expansion.
Market consolidation and increased industry focus on CNS and rare disease innovation enhance the potential for strategic partnerships, licensing, or acquisition opportunities, which could drive long-term earnings growth and unlock additional shareholder value.

ACADIA Pharmaceuticals Earnings and Revenue Growth

ACADIA Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ACADIA Pharmaceuticals's revenue will grow by 13.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 36.5% today to 18.3% in 3 years time.
Analysts expect earnings to reach $286.9 million (and earnings per share of $1.53) by about April 2029, down from $391.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $504.6 million in earnings, and the most bearish expecting $113.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.5x on those 2029 earnings, up from 9.9x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
Analysts expect the number of shares outstanding to grow by 1.87% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.1%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing U.S. pharmaceutical price controls and upcoming IRA price negotiations (potentially as soon as 2029), especially for NUPLAZID's Medicare-dominant patient population, could limit ACADIA's pricing power, compressing future revenue growth and net margins.
Heavy reliance on NUPLAZID for overall revenue (currently $168.5M out of $264.6M total revenue) creates significant concentration risk; any regulatory, safety, reimbursement, or exclusivity concerns-especially after 2038 or due to generic pressure-could sharply reduce top-line revenue and earnings.
R&D pipeline expansion is accompanied by steadily rising R&D and SG&A costs (SG&A up from $117.1M to $133.5M YoY), and any setbacks in clinical trials, regulatory roadblocks, or failed readouts across the 9 disclosed programs could result in increased cash burn and negative margin impact.
Increasing competition in neurological and CNS disorders, both from larger pharmas prioritizing these high-demand markets and from potential generics as NUPLAZID nears patent expiration, poses long-term threats to ACADIA's market share, leading to pressured revenues and thinner margins.
The limited addressable population for products like DAYBUE (Rett syndrome) could result in growth plateauing if community-based adoption does not accelerate as forecasted or if persistency rates fall, restricting the scale needed for significant long-term earnings expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $31.8 for ACADIA Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $45.0, and the most bearish reporting a price target of just $17.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $286.9 million, and it would be trading on a PE ratio of 24.5x, assuming you use a discount rate of 7.1%.
Given the current share price of $22.6, the analyst price target of $31.8 is 28.9% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ACADIA Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Global Outreach And Pipeline Programs Will Expand CNS Markets